| pubmed-article:11181146 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:11181146 | lifeskim:mentions | umls-concept:C0019693 | lld:lifeskim |
| pubmed-article:11181146 | lifeskim:mentions | umls-concept:C0242510 | lld:lifeskim |
| pubmed-article:11181146 | lifeskim:mentions | umls-concept:C0036864 | lld:lifeskim |
| pubmed-article:11181146 | lifeskim:mentions | umls-concept:C1533685 | lld:lifeskim |
| pubmed-article:11181146 | lifeskim:mentions | umls-concept:C0199176 | lld:lifeskim |
| pubmed-article:11181146 | lifeskim:mentions | umls-concept:C0332157 | lld:lifeskim |
| pubmed-article:11181146 | lifeskim:mentions | umls-concept:C2603343 | lld:lifeskim |
| pubmed-article:11181146 | lifeskim:mentions | umls-concept:C0036152 | lld:lifeskim |
| pubmed-article:11181146 | pubmed:issue | 5 | lld:pubmed |
| pubmed-article:11181146 | pubmed:dateCreated | 2001-2-22 | lld:pubmed |
| pubmed-article:11181146 | pubmed:abstractText | The feasibility of providing postexposure prophylaxis (PEP) after sexual or injection drug use exposures to human immunodeficiency virus (HIV) was evaluated. PEP was provided within 72 h to individuals with exposures from partners known to have or to be at risk for HIV infection. PEP consisted of 4 weeks of antiretroviral medications and individually tailored risk-reduction and medication-adherence counseling. Among 401 participants seeking PEP, sexual exposures were most common (94%; n=375). Among sexual exposures, receptive (40%) and insertive (27%) anal intercourse were the most common sexual acts. The median time from exposure to treatment was 33 h. Ninety-seven percent of participants were treated exclusively with dual reverse-transcriptase inhibitors, and 78% completed the 4-week treatment. Six months after the exposure, no participant developed HIV antibodies, although a second PEP course for a subsequent exposure was provided to 12%. PEP, after nonoccupational HIV exposure, is feasible for persons at risk for HIV infection. | lld:pubmed |
| pubmed-article:11181146 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11181146 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11181146 | pubmed:language | eng | lld:pubmed |
| pubmed-article:11181146 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11181146 | pubmed:citationSubset | AIM | lld:pubmed |
| pubmed-article:11181146 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11181146 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11181146 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11181146 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11181146 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11181146 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11181146 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:11181146 | pubmed:month | Mar | lld:pubmed |
| pubmed-article:11181146 | pubmed:issn | 0022-1899 | lld:pubmed |
| pubmed-article:11181146 | pubmed:author | pubmed-author:ChambersDD | lld:pubmed |
| pubmed-article:11181146 | pubmed:author | pubmed-author:CoatesT JTJ | lld:pubmed |
| pubmed-article:11181146 | pubmed:author | pubmed-author:KralV AVA | lld:pubmed |
| pubmed-article:11181146 | pubmed:author | pubmed-author:MartinJ NJN | lld:pubmed |
| pubmed-article:11181146 | pubmed:author | pubmed-author:KatzM HMH | lld:pubmed |
| pubmed-article:11181146 | pubmed:author | pubmed-author:ChesneyMM | lld:pubmed |
| pubmed-article:11181146 | pubmed:author | pubmed-author:BambergerJ... | lld:pubmed |
| pubmed-article:11181146 | pubmed:author | pubmed-author:RolandM EME | lld:pubmed |
| pubmed-article:11181146 | pubmed:author | pubmed-author:FransesKK | lld:pubmed |
| pubmed-article:11181146 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:11181146 | pubmed:day | 1 | lld:pubmed |
| pubmed-article:11181146 | pubmed:volume | 183 | lld:pubmed |
| pubmed-article:11181146 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:11181146 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:11181146 | pubmed:pagination | 707-14 | lld:pubmed |
| pubmed-article:11181146 | pubmed:dateRevised | 2007-11-14 | lld:pubmed |
| pubmed-article:11181146 | pubmed:meshHeading | pubmed-meshheading:11181146... | lld:pubmed |
| pubmed-article:11181146 | pubmed:meshHeading | pubmed-meshheading:11181146... | lld:pubmed |
| pubmed-article:11181146 | pubmed:meshHeading | pubmed-meshheading:11181146... | lld:pubmed |
| pubmed-article:11181146 | pubmed:meshHeading | pubmed-meshheading:11181146... | lld:pubmed |
| pubmed-article:11181146 | pubmed:meshHeading | pubmed-meshheading:11181146... | lld:pubmed |
| pubmed-article:11181146 | pubmed:meshHeading | pubmed-meshheading:11181146... | lld:pubmed |
| pubmed-article:11181146 | pubmed:meshHeading | pubmed-meshheading:11181146... | lld:pubmed |
| pubmed-article:11181146 | pubmed:meshHeading | pubmed-meshheading:11181146... | lld:pubmed |
| pubmed-article:11181146 | pubmed:meshHeading | pubmed-meshheading:11181146... | lld:pubmed |
| pubmed-article:11181146 | pubmed:meshHeading | pubmed-meshheading:11181146... | lld:pubmed |
| pubmed-article:11181146 | pubmed:meshHeading | pubmed-meshheading:11181146... | lld:pubmed |
| pubmed-article:11181146 | pubmed:meshHeading | pubmed-meshheading:11181146... | lld:pubmed |
| pubmed-article:11181146 | pubmed:meshHeading | pubmed-meshheading:11181146... | lld:pubmed |
| pubmed-article:11181146 | pubmed:meshHeading | pubmed-meshheading:11181146... | lld:pubmed |
| pubmed-article:11181146 | pubmed:meshHeading | pubmed-meshheading:11181146... | lld:pubmed |
| pubmed-article:11181146 | pubmed:meshHeading | pubmed-meshheading:11181146... | lld:pubmed |
| pubmed-article:11181146 | pubmed:meshHeading | pubmed-meshheading:11181146... | lld:pubmed |
| pubmed-article:11181146 | pubmed:meshHeading | pubmed-meshheading:11181146... | lld:pubmed |
| pubmed-article:11181146 | pubmed:meshHeading | pubmed-meshheading:11181146... | lld:pubmed |
| pubmed-article:11181146 | pubmed:meshHeading | pubmed-meshheading:11181146... | lld:pubmed |
| pubmed-article:11181146 | pubmed:meshHeading | pubmed-meshheading:11181146... | lld:pubmed |
| pubmed-article:11181146 | pubmed:meshHeading | pubmed-meshheading:11181146... | lld:pubmed |
| pubmed-article:11181146 | pubmed:year | 2001 | lld:pubmed |
| pubmed-article:11181146 | pubmed:articleTitle | Feasibility of postexposure prophylaxis (PEP) against human immunodeficiency virus infection after sexual or injection drug use exposure: the San Francisco PEP Study. | lld:pubmed |
| pubmed-article:11181146 | pubmed:affiliation | Positive Health Program, Dept. of Medicine, University of California-San Francisco, at San Francisco General Hospital, 995 Potrero Ave., San Francisco, CA 94110, USA. jkahn@php.ucsf.edu | lld:pubmed |
| pubmed-article:11181146 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:11181146 | pubmed:publicationType | Research Support, U.S. Gov't, P.H.S. | lld:pubmed |
| pubmed-article:11181146 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11181146 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11181146 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11181146 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11181146 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11181146 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11181146 | lld:pubmed |
